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Abstract 
During development, the cell secretes growth and differentiation factors (GDFs) to the 
surrounding microenvironment. These factors are often key regulators of o rganogenesis 
and embryogenesis. Several GDFs carry sequences that mediate specific interaction with 
molecules of the extracellular matrix (ECM) that surrounds the cell. The deposition of 
factors in the matrix can theoretically result in (1) reservoirs of growth factors, (2) in 
spatially restricted action range of the factor or (3) in the critical growth factor 
concentrations or gradients needed for the factor to elicit specific cellular responses i.e. to 
act as a morphogen. So far, few attempts have been made to analyse the functional 
importance of GDF-ECM interactions. Several platelet-derived growth factor (PDGF) 
and vascular endothelial growth factor (VEGF) family members display basic amino acid 
motifs at the C-terminus, which confer retention of the factor in the extracellular milieu 
surrounding the producing cell. T o address the role of PDGF-B retention in vivo, we 
deleted the retention motif in mice by a gene targeting approach. This resulted in 
reduced recruitment and defective investment of pericytes in the micro-vessel wall, and in 
delayed formation of the glomerular mesangium. Long-term effects of lack of PDGF-B 
retention included reactive gliosis in the CNS, severe retinal detoriation, 
glomerulosclerosis and proteinuria. Several tumours express PDGF-B and the cognate 
receptor PDGFR-ß. To investigate the effects of altered PDGF-B distribution in a 
pathological situation, we analysed the vasculature in a tumour model. In tumours 
transplanted to PDGF retention deficient mice, pericytes were fewer and partially 
detached, leading to significantly increased vessel diameter and haemorrhaging. Tumour 
specific over-expression of PDGF-B increased the pericyte density in both control and in 
PDGF-B retention deficient mice, but could not correct the defective pericyte 
integration in the vascular wall. To analyse developmental effects of PDGF over-
expression, we generated transgenic mice that over-expressed different PDGF isoforms 
specifically in the heart. This caused pathological changes ranging from severe and 
generalised cardiac fibrosis and early postnatal lethality to focal fibrosis in the adult heart. 
Thus, PDGF signalling seems sufficient to induce cardiac fibrosis. In conclusion, the 
alteration of PDGF distribution or increased/decreased PDGF levels, h ave detrimental 
effects during development, as well as in t he adult. The results point to an important role 
for PDGF in cancer and on retinal, glomerular and myocardial diseases. 
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Abstract 
During development, the cell secretes growth and differentiation factors (GDFs) to the 
surrounding microenvironment. These factors are often key regulators of organogenesis 
and embryogenesis. Several GDFs carry sequences that mediate specific interaction with 
molecules of the extracellular matrix (ECM) that surrounds the cells. The deposition of 
factors in the matrix can theoretically result in (1) reservoirs of growth factors, in (2) 
spatially restricted action range of the factor or in (3) the critical growth factor 
concentrations or gradients needed for the factor to elicit specific cellular responses i.e. to 
act as a morphogen. So far, few attempts have been made to analyse the functional 
importance of GDF-ECM interactions. Several platelet-derived growth factor (PDGF) 
and vascular endothelial growth factor (VEGF) family members display basic amino acid 
motifs at the C-terminus, which confer retention of the factor in the extracellular milieu 
surrounding the producing cell. To address the role of PDGF-B retention in vivo, we 
deleted the retention motif in mice by a gene targeting approach. This resulted in reduced 
recruitment and defective investment of pericytes in the micro-vessel wall, and in delayed 
formation of the glomerular mesangium. Long-term effects of lack of PDGF-B retention 
included reactive gliosis in the CNS, severe retinal detoriation, glomerulosclerosis and 
proteinuria. Several tumours express PDGF-B and the cognate receptor PDGFR-ß. To 
investigate the effects of altered PDGF-B distribution in a pathological situation, we 
analysed the vasculature in a tumour model. In tu mours transplanted to PDGF retention 
deficient mice, pericytes were fewer and partially detached, leading to significantly 
increased vessel diameter and haemorrhaging. Tumour specific over-expression of 
PDGF-B increased the pericyte density in both control and in PDGF-B retention deficient 
mice, but could not correct the defective pericyte integration in the vascular wall. To 
analyse developmental effects of PDGF over-expression, we generated transgenic mice 
that over-expressed different PDGF isoforms specifically in the heart. This caused 
pathological changes ranging from severe and generalised cardiac fibrosis and early 
postnatal lethality to focal fibrosis in the adult heart. Thus, PDGF signalling seems 
sufficient to induce cardiac fibrosis. In conclusion, the alteration of PDGF distribution or 
increased/decreased PDGF levels, have detrimental effects both during development, and 
in the adult. The results point to an important role for PDGF in cancer and on retinal, 
glomerular and myocardial diseases. 
Key words: PDGF, pericyte, cancer, fibrosis, ECM, HSPG, cell retention, angiogenesisl 
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Abbreviations 
BM basement membrane 
CUB domain found in complement urchin-like EGF 
protein and bone morphogenetic protein-1 
dally division abnormally delayed 
E embryonic day 
EC endothelial cell 
ECM extracellular matrix 
EGF epidermal growth factor 
FGF fibroblast growth factor 
GAG glucosaminoglycan 
GDF growth and differentiation factor 
GDNF glial-derived neurotrophic factor 
GlcA glucuronic acid 
GlcNAc N-acetylglucoseamine 
HSPG heparan sulfate proteoglycan 
MHC myosin heavy chain 
MTC Masson-tri-chrome 
NDST N-deacetylase/N-sulfotransferase 
P postnatal day 
PDG F platelet-derived growth factor 
PDGFR platelet-derived growth factor receptor 
P1GF placenta growth factor 
Shh sonic hedgehog 
SH2 src homology 2 domain 
SMA a-smooth muscle actin 
SPARC secreted protein, acidic, and rich in cysteine 
SSV simian sarcoma virus 
TGF transforming growth factor 
TNF tumour necrosis factor 
VEGF vascular endothelial growth factor 
vSMC vascular smooth muscle cell 
Wg wingless 
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Introduction 
Embryonic development has fascinated us and been subject for study since 
ancient times. It was not until the late 19th century, when classical 
anatomical embryology, experimental embryology and genetics began to 
address the common and central question of how a multicellular organism 
can develop from a single primordial cell, the zygote. Although there was a 
split between classical genetics and embryology in the 1920's, the recent 
decades have merged them again and it is now apparent that the two 
disciplines are closely linked and dependent on each other. 
The completion of the human genome sequence project in 2001 set a 
milestone in the genetic research. The three billion nucleotide mammalian 
genome contains about 40,000 genes and we are just beginning to realise the 
complex nature of it s regulation. We are also only a t the start of addressing 
the specific function(s) of each individual gene. One of the most powerful 
inventions that have helped us study gene functions in the context of the 
living organism in vivo is gene targeting. This approach allows us to 
introduce specific alteration in any gene of interest. The effect of the 
mutated gene can be analysed in the developing or adult organism and 
during normal and pathological conditions. Gene targeting in mice has been 
utilised in the work described in this thesis. Firstly, we have introduced a 
mutation in the platelet-derived growth factor-b (pdgf-b) gene, which 
changes the way the PDGF-B protein distributes in the cellular interstitium. 
We analysed the consequences of this mutation in several organs, including 
kidney and retina. Secondly, we analysed the consequences of this mutation 
in a pathological situation. We chose a well-characterised tumour model and 
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studied its progression in the background of the PDGF mutation. Thirdly, by 
a classical transgenic approach we over-expressed three forms of PDGFs 
under the control of a heart-specific promoter and analysed resulting 
pathological responses. 
The tools that we have applied and the way we are now able to analyse the 
genome, demonstrate how closely linked genetics and developmental 
biology have become. However, while it is now possible to manipulate the 
genotype with high precision, it is still difficult to interpret the phenotypic 
consequences of such manipulations. To reach mechanistic insight, it is 
necessary to do careful analyses of gene expression patterns and protein 
distribution. In addition, it is as necessary to follow the time course 
progression of the phenotypic consequences, in order to discern primary 
from secondary effects. This will be very clear in the first part of the thesis, 
which deals with one of the most complex component of our bodies, the 
extracellular matrix (ECM). I initially discuss the main components of the 
ECM to illustrate the dynamic environment that surrounds the cell and what 
milieu the growth factors face upon secretion. The first part also exemplifies 
several proteins potentially important for the interactions between the ECM 
and PDGF. While condensed and far from comprehensive, this general 
description of the ECM is necessary for the subsequent discussion of my 
results. The description also serves as an illustration to the recent advances 
and limitations of gene-targeting experiments. 
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General background 
The extracellular matrix 
The ECM was previously referred to as "connective tissue", which is a 
misleading term that implies a stable and uniform mesh with a simple 
function; to connect and scaffold cells in our bodies. Data accumulated over 
the last two decades show the contrary: the ECM is a highly dynamic 
complex of substances, which shows unique composition in different organs 
and functional states, and plays a number of critical roles in the regulation of 
cell function. The ECM has major impact on development and on disease 
processes such as diabetic nephropathy, cancer and fibrotic conditions. 
These diseases will be further discussed in t he sections relating to papers I, 
II and III, resp ectively. The ECM can affect the d ifferentiation state of the 
individual cell, and thereby also the factors that the cell delivers to its 
environment. Moreover, the ECM composition influences the function and 
distribution of certain growth and differentiation factors (GDFs). The ECM 
distributes between two major domains, the basement membranes (BM) and 
the interstitial matrix. The BM is located adjacent to e.g. epithelial and 
endothelial cells, adipocyte and muscle cells. The BM serves both as a unit 
that separates cells, or as a substrate, on which the cell can migrate, 
proliferate and differentiate. 
Collagen and the basement membrane 
Collagen constitutes 50% of the basement membrane, which additionally 
contains approximately 50 different proteins. The dominant collagen isoform 
varies depending on the tissue. Collagen I is widely expressed (except for 
1 1  
cartilage), while expression of collagen II is restricted to cartilage and the 
eye. So far, more than 20 genetically distinct types of collagen have been 
identified. Expression of collagen is localised to cells present in the tissue 
stroma (fibroblasts, chondrocytes, osteoblasts, myofibrobroblasts). However, 
certain epithelial and endothelial cells also produce collagens e.g. collagen 
type IV. All collagens are characterised by a repetitive amino acid sequence, 
in which every third amino acid is a glycine (so called Gly-X-Y motif). 
Collagen subtypes I, II, III, V and XI carry long such stretches and have the 
ability to form fibrils, which act as supportive elements of tendons, cartilage, 
bone and skin. Fibril formation takes place in the ECM, where specific 
metalloproteinases cleave the procollagen. Some collagens are not able to 
form fibrils, but rather form net-like structures. Collagen IV is also known as 
"network forming collagen" and is the major component of basement 
membranes. Collagen type VI, IX, XII and XIV associate with fibril 
structures, and finally collagen type XIII is transmembranous (reviewed in 
Kalluri 2003). 
Extracellular glycoproteins 
The ECM consists of several other proteins besides collagen. One of the 
main components is laminin. Laminins exist in several isoforms that, in 
different combinations, form the functional protein. The mature laminins 
consist of three disulphide-linked polypeptide chains. Production of the 
isoforms is tissue-specific. Different laminins induce different effects in 
cells, including differentiation, adhesion and cell migration. Laminins 
interact with cells mainly through integrins. Metalloproteinases (MMPs) are 
able to cleave laminins, enabling cell detachment from the ECM and cell 
migration. Laminins are able to bind collagens, which is important for the 
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establishment of the ECM. In a tumour, aberrant laminin expression often 
correlates with defective interaction between invading tumour cells and the 
ECM. Hence, altered laminin expression is thought to be an important 
feature in cancer progression (reviewed in Bosman and Stamenkovic 2003). 
Fibronectin (FN) is another large ECM protein (460 kDa), which is 
synthesised both in normal and pathological conditions. FN is mainly 
produced by fibroblasts, chondrocytes, endothelial cells, macrophages and 
certain types of epithelial cells. FN functions as an adhesive molecule by 
binding to integrins, but it also binds collagen, thereby contributing to the 
organisation of the ECM. FN forms a substrate for migrating cells. For 
example, germ cells that migrate from the yolk sac to the developing gonads 
depend on interactions with FN. FN has heparin and heparan sulfate 
proteoglycan (HSPG) binding sites. The interaction with HSPGs may affect 
cell adhesion, and the presentation of HSPG-bound growth factors to the cell 
(reviewed in Pankov and Yamada 2002). 
Tenascin has a complex domain structure and can bind to several molecules 
on the cell surface, including integrins, Ig cell adhesion molecules (CAMs) 
and phosphacan (a chondroitin sulphate proteoglycan). Expression of 
tenascin at sites of ongoing matrix rearrangement coincides with the 
expression of MMPs. MMPs may cleave tenascin and thereby affect the 
cellular functions dependent on tenascin interactions with the ECM. 
Tenascin is normally not expressed in the adult, however, re-expression is 
detected during neovascularisation and tumour growth (reviewed in Jones 
and Jones 2000). 
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Similar to tenascin, SPARC (secreted protein acidic and rich in c ysteine) is 
ubiquitously expressed during development. SPARC is down-regulated in 
the adult and re-expressed at sites of ongoing remodelling and wound 
healing. SPARC and PDGF-B co-localise in platelet a-granules and show a 
pH dependent interaction. This may influence the release of PDGF in e.g. 
wound healing. Moreover, SPARC has an inhibitory effect on vascular 
endothelial growth factor, fibroblast growth factor and PDGF-A signalling. 
The spectrum of SPARC-growth factor interactions suggests that SPARC 
may have a regulative rather than a structural function in the ECM (Raines et 
al. 1992; reviewed in Brekken and Sage 2001). 
Proteoglycans 
Proteoglycans consist of a protein core with connected sugar polymers 
glycosaminoglycans (GAGs). The GAGs are attached in a linear fashion to 
serine residues on the protein core and are subject to specific modifications, 
other glycoproteins carry unmodified sugar chains that are often branched. 
The sugar polymers consist of multiple and distinct disaccharide units. 
Heparan, for example, consists of glucuronic acid (GlcA) and N-
acetylglucosamine (GlcNAc), whereas chondroitin consists of repetitive 
disaccharides of N-acetylgalactosamin and GlcA. Heparan sulfate 
proteoglycan (HSPG) is a form of proteoglycans that carries sulfated GAG 
chains. The sulfate groups provide the GAG chains with a negative charge, 
mediating interaction with positively charged domains of many proteins, for 
example PDGF/VEGF family members. The relative amount of HSPG 
versus collagen determines the plasticity/rigidity of the ECM. The 
localisation of HSPGs to the cell surface likely makes them important for 
cell-cell interaction. Recently, HSPGs have been shown to be important for 
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growth factor signalling during development. Despite being such a complex 
family of molecules, the genetics of the HSPGs is fairly simple. All 
members of the five different classes; syndecan, glypican, perlecan, agrin 
and collagen type XVIII, are encoded by a total o f 13 separate genes. These 
genes are thought to account for at least 95 % of the total numbers of 
proteoglycans in the ECM (reviewed in Iozzo 2001). On the other hand, 
HSPGs display an enormous heterogeneity, mostly depending on the 
multiple serine residues present on the core proteins where the GAGs can 
bind. Alternative splicing of the genes, proteolytic processing and different 
modifications of the GAG chains further increase the complexity of the 
HSPGs. The physical nature of the HSPGs enables them to span a distance 
of several hundred nanometers, making it possible for them to reach over an 
entire basement membrane and contact adjacent cells. Obviously, it is 
interesting to consider the multiple potential implications of such features 
for growth factor distribution and action. Accordingly, presence of HSPGs 
has been shown to be required for activation of the fibroblast growth factor 
receptor (FGFR) by FGF (Yayon et al. 1991a). The heparan sulfate structure 
does not d epend on the core protein. Rather, a given cell produces heparan 
sulfates of similar structure that may become attached to different core 
proteins. HSPGs contact the ECM in d ifferent ways (outlined in figure 1). 
The four syndecans are transmembranous proteins with the heparan sulfate 
chains near the extracellular tips and chondroitin sulfate chains near the cell 
surface. The six members of the glypicans attach to the cell membrane 
through a glycosylphosphatidylinositol (GPI)-anchor. Perlecan, agrin and the 
HSPG/collagen type XVIII are located in the pericellular space. 
15 
Synthesis of proteoglycans involves several enzymatic steps. It starts with 
the addition of a tetrasaccharide linker to a serine residue on the core 
protein. Xylosyltransferase adds a single xylose to the serine residue, which 
constitutes the first piece of the linker. Next follows the addition of two 
galactose units, catalysed by two different galactosyltransferases. Finally, a 
single GlcNAc is added, which completes the formation of the 
tetrasaccharide linker (Lander and Selleck 2000; Esko and Lindahl 2001 ). 
Next, two transferases initiate the polymerisation reaction by the addition of 
GlcNAc-GlcA disaccharide residues. These polymerisation enzymes are 
encoded by the mammalian EXT gene family. The disaccharides can 
subsequently be modified e.g. by sulfation, such as N-deacetylation/N-
sulfation (removal of the acetyl group from the N atom, followed by sulfate 
addition to the same N) and O-sulfation (addition of a sulfate group to one of 
the hydroxyl groups of the sugar ring). Sulfation is by far the most important 
reaction for generating diversity within the proteoglycans. N-sulfation is 
performed by four members of the N-deacetylase/N-sulfotransferase 
(NDST) family. 
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periecan 
syndecans 
type XVIII collagen 
ECM 
glypicans 
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Cytosol 
Figure I. A schematic depiction of heparan sulfate proteoglycans. Syndecans are 
transmembrane proteoglycans, while glypican core proteins are linked via a 
phosphoinositol anchor to the cell membrane. Collagen type XVIII, agrin and 
periecan are secreted proteins, but are retained in close vicinity to the producing 
cell and are components of the basement membrane. Branches indicate 
glycosaminoglycan side chains; e.g., periecan usually carries three HS chains 
near the N-terminus. 
Functional studies on ECM molecules 
The high c oncentration of HSPGs in the ECM, their extraordinary half-life 
numbers, their negative charge, and their ability to interact with GDFs of 
numerous families, together make the HSPGs unique among the ECM 
components. The HSPGs interaction with GDFs enables formation of 
gradients, necessary for morphogenetic processes during development 
(Perrimon and Bernfield 2000). Also, GDF signalling properties may depend 
on HSPGs. For example, FGF depends on the presence of HSPGs on the 
responding cell surface for optimal receptor binding and activation (Yayon 
et al. 1991b). Several attempts have aimed at pinpointing the function(s) of 
HSPGs in the intact organism. The most advanced and productive studies 
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have utilised mutation screens in th e fruit fly Drosophila melanogaster and 
gene targeting in mice. 
For genetic analyses on HSPGs, two principally different approaches may be 
considered. Firstly, the core protein may be inactivated. In this situation, 
similar HS side chains might still be present on other core proteins, leading 
to functional redundancy or compensation and lack of phenotypic outcome. 
The core protein itself c an also have structural or other functions, without 
associated HS side chains, so the phenotypic outcome of core protein 
ablation may be related to the functions of HSPGs. One might therefore need 
to compare the result of core protein ablatio n with t he phenotypic outcome 
of specific mutations of the HS attachment sites. Secondly, enzymes 
involved in the HS polymerisation or modification processes may be 
targeted by mutagenesis. This may, however, lead to very complex 
phenotypes, since it would affect the modifications on all core proteins. 
HSPGs core protein mutants in Drosophila 
In vertebrates, the HSPGs include glypican, perlecan, agrin, collagen and 
syndecan. However, the Drosophila genome contains only one syndecan, 
two glypicans and one perlecan homologue. The two glypicans are named 
dally (division abnormally delayed) (Nakato et al. 1995) and dally-like 
(Khare and Baumgartner 2000), while syndecan is known as Dsyndecan 
(Spring et al. 1994). Dally has been inactivated in flies through mutation or 
RNA interference. Interestingly, dally mutants phenocopy the wingless (Wg) 
mutant. Wg is a GDF important for patterning processes in Drosophila. 
Several studies have confirmed that the levels and expression patterns of 
dally and dally-like protein have pronounced positive effect on Wg signaling 
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(Lin and Perrimon 1999; Tsuda et al. 1999; Baeg et al. 2001). This was one 
of the first pieces of compelling evidence for a specific function for HSPGs. 
HSPGs modification enzyme mutants in Drosophila 
Drosophila mutants have also been studied for the homologue of UDP-D-
glucose dehydrogenase, which produces UDPGlcA, and the NDST 
homologue. These mutations affect polymerisation (sugarless) and sulfation 
(sulfateless), respectively. Alteration of these enzymes has pronounced 
negative effect on the signalling pathways of Wg, FGF and Hedgehog (Hh) 
(Binari et al. 1997; Hacker et al. 1997; Lin et al. 1999). Consequently, the 
severe phenotypes associated with these mutations mimic complete loss of 
the signalling pathways induced by these factors, highlighting the 
importance of HSPGs during development. 
The interaction between GDFs and HSPGs can be very specific, as 
demonstrated by fibroblast growth factor-2 (FGF-2) and hepatocyte growth 
factor (HGF). FGF-2 needs three consecutive trisulfated disaccharides units 
to bind efficiently to HS (Faham et al. 1996). HGF, on the other hand, 
requires a pentasaccharide to bind to heparin (Ashikari et al. 1995). A 
mutation in on e EXT homologue (polymerisation enzyme) further enhances 
the view that proteoglycans interact with growth factors more specifically 
than previously expected. One would expect this mutant (tout velu) to have 
similar consequences as sulfateless or sugarless. However, only the Hh 
signalling pathway seems to be affected. This specificity is surprising, since 
no core proteins would be expected to carry HS side chains (Bellaiche et al. 
1998; The et al. 1999). However, one should bear in mind that the most 
sensitive and non redundant pathways are most likely to generate a 
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phenotype when disturbed. Hence, these results do not rule out a function for 
HS side chains in Wg or FGF signalling. 
HSPGs core protein mutants in mouse 
The studies referred to above demonstrates the challenge involved in 
interpreting Drosophila phenotypes, into specific biochemical interactions, 
due to the complexity of the intact Drosophila larvae. Thus, the challenge to 
interpret phenotypic alterations in mice might be expected to be even larger, 
in particular considering the higher complexity of the mouse genome. For 
example, the mouse has four NDST and six glypican genes, compared to the 
fly, which has one NDST (sulfateless) and two glypican genes (dally and 
dally-like) (Table 1). Additionally, the mouse genome contains more GDFs 
and, most likely, produces a more complex pattern of protein isoforms. 
However, several core proteins have been genetically targeted in mice and 
the phenotypes vary from embryonic lethality, e.g. deletion of perlecan 
(Arikawa-Hirasawa et al. 1999; Costell et al. 1999) to situations where no 
abnormalities are observed e.g. deletion of glypican-2 (Lander and Selleck 
2000). 
In mice, the core proteins perlecan, agrin and collagen XVIII, have been 
genetically ablated. Perlecan-deficient mice display severe abnormalities, 
not resembling any of the mutants of the enzymes involved in GAG 
polymerization or modification pathways (reviewed in Forsberg and Kjellen 
2001). The perlecan mutant passes through two critical time points. At 
embryonic day (E) 10-12, many of the mutants die due to defective 
organisation of the cardiac basement membranes and subsequent rupture. 
Survivors of this first critical stage die at birth, due to exencephaly or similar 
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malformation. As previously discussed, this may reflect a function of the 
perlecan core protein without attached HS side chains. Perlecan interacts 
both with the ECM components collagen type IV and nidogen I, but it can 
also bind directly to e.g. FGF-7 (Mongiat et al. 2000). In a recent elegant 
study, exon three of perlecan was specifically altered abolishing the 
initiation sites for three HS side chains (Rossi et al. 2003). These mice 
developed normally and were fertile, but their lenses degenerated 
postnatally. This phenotype was restricted to the eyes and became worse in 
the background of a collagen XVIII mutation, suggestive for overlapping 
functions of perlecan and collagen XVIII HSPGS in the lens. 
Agrin homozygous null mice display defects in presynaptic differentiation, 
intramuscular nerve branching and other nerve-specific alterations (Gautam 
et al. 1996). Mice carrying a null mutation in t he collagen XVIII gene show 
delayed regression of the hyaloid vessels (hyaloid vessels normally nurture 
the lens during development and regress after birth, when lens growth has 
ceased). These mice also display irregular sprouting of the endothelial cells 
from the optic disc into the retina. The retinal defect might be secondary to 
lower levels of VEGF, due to increased oxygen pressure in the retina as a 
result of persisting hyaloid vasculature (Fukai et al. 2002). For description of 
retinal development, see the section below relating to paper I. 
Mouse mutants for the cell surface proteoglycans include syndecan-1,-4, and 
glypican-2, -3. Syndecan-1, -4 and glypican-2 deficient mice develop 
normally (reviewed in Forsberg and Kjellen 2001). Glypican-3 null mutants 
die perinatally and display developmental overgrowth, cystic and dysplastic 
kidneys and abnormal lung development (Cano-Gauci et al. 1999). 
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Interestingly, a later study linked the kidney phenotype, in the glypican-3 
mice, to the loss of BMP-2 inhibitory effect on kidney tubular branching 
(Grisaru et al. 2001). 
HSPG modification enzyme mutants in mouse 
Mice carrying targeted mutations in the genes coding for enzymes involved 
in polymerisation and modifications of the HS side chains include two 
NDST isoforms, one polymerase enzyme (EXT-1) and a 2-0-
sulfotransferase. Mice heterozygous for an EXT-1 null allele (homologous 
to Drosophila tout velu), show reduced HS production, whereas 
homozygotes die during gastrulation and show abnormally organised 
mesoderm and extraembryonic tissues (Lin et al. 2000). Thus, the removal 
of most of the HS side chains from all core proteins resulted in a more 
severe phenotype than the removal of any of the core proteins. 
NDSTs are necessary for the sulfation of the side chains and are homologous 
to Drosophila sulfateless. Mouse mutants have been produced for NDST-1 
and -2. NDST-1 mutants show, as expected, reduced levels of N-sulfated 
HS. The mutants display defective production of surfactants in the lungs, 
which leads to death shortly after birth. They also show skeletal and eye 
defects. NDST-2 mice show a defect in the connective tissue type mast-cells. 
The mast-cells were almost devoid of granules, which normally contains e.g. 
heparin, proteases and histamine that are released during an inflammatory 
state. The phenotype was in line with previous data; no compensation could 
occur since NDST-1 is absent in these cells. However, the embryonic 
lethality of double NDST-1 and -2 mice suggests that NDST-2 is partially 
redundant with NDST-1 (Forsberg and Kjellen 2001). For complete 
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description of NDST mutants see (Forsberg et al. 1999; Humphries et al. 
1999). 
Drosophila Mice 
Core proteins 
glypican 
syndecan 
Enzymes 
UDP-D-glucose dehydrogenase 
IN-deacetylase/N-sulphotransferase 
GlcNAe/GIcA polymerase 
Dally, Dally-like 
Dsyndecan 
sugarless 
sulfateless 
tout velu 
glypican-1, -2, -3, -4, -5, -6 
syndecan- 1, -2, -3, -4 
ugdh 
NDST-1,-2, -3, -4 
Ext I , Ext 2 
Table 1. An outline of the described core proteins, polymerisation/modification 
enzymes and mice/Drosophila homologues 
In summary, the ECM is a dynamic complex of many different types of 
molecules. Its interaction with GDFs is critically important in developmental 
processes and may be more specific than previously expected. Investigations 
of different mutants of core proteins and HS side chains producing enzymes 
are ongoing and will most likely add more clues to the functions of HSPGs. 
This introduction will now be followed by a section describing some of the 
factors secreted into and interacting with the ECM. PDGF is one of many 
protein families where certain isoforms carry specific amino acid residues 
that interact with HSPGs. The exact HSPG binding partners for PDGFs in 
vivo have, however, not yet been identified. 
Introduction to Platelet-derived growth factor 
The use of the term growth and differentiation factors (GDFs), rather than 
growth factors, throughout this thesis better reflects the functional diversity 
of this large group of proteins. Many of the individual GDF names originate 
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from the source of purification or the first cell type known to be affected. 
Later on, with improved technology and knowledge, we have realised that 
most GDFs are highly pleiotropic in their functions. Thus, factors like EGFs, 
PDGFs, Hh, FGFs and TGFs can affect migration, differentiation, 
apoptosis/survival, proliferation and other cellular functions. Several of 
these factors conduct an intrinsic interaction with the molecules in the ECM. 
GDFs can either bind directly to the core protein, such as FGF-7 and TGF-
ß (Andres et al. 1989; Mongiat et al. 2000) or interact with the heparan 
sulfate side chains, such as PDGF, VEGF and FGF-2 (Moscatelli 1988; 
Houck et al. 1992; Pollock and Richardson 1992; Kelly et al. 1993). In some 
cases, the GDF-ECM interaction is necessary for optimal receptor activation. 
In other cases, the interaction mediates retention of the factor close to the 
cell. To date, only few studies have addressed the functional importance of 
GDF-ECM interactions in vivo. This thesis includes one of the first attempts 
to analyse the importance of such interactions in vertebrates. Because my 
work has been based on PDGFs, I provide an introduction to this family of 
growth factors below. 
Platelet derived growth factor - general background 
PDGF was originally identified as a factor within blood serum plasma 
(Kohler and Lipton 1974; Ross et al. 1974; Westermark and Wasteson 
1976). It was subsequently purified from human platelets (Antoniades et al. 
1979; Deuel et al. 1981). Early in vitro experiments showed that PDGF 
could induce mitosis (Cochran et al. 1983), induce collagen synthesis 
(Canalis 1981), act as neurotrophic agent (Smits et al. 1991), affect the 
differentiation on mesenchymal cells (Noble et al. 1988) and induce 
Chemotaxis (Grotendorst et al. 1982a; Seppa et al. 1982; Kundra et al. 1994). 
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A breakthrough in the PD GF field, which attracted much a ttention, involved 
the identification of the tra nsforming gene product of Simian Sarcoma Virus 
(SSV). This product, the v-sis protein, turned out to be a virally transduced 
homologue of PDGF-B (Devare et al. 1983; Doolittle et al. 1983; Waterfield 
et al. 1983). 
The in vitro stimulatory properties of PDGF on fibroblasts, smooth muscle 
cells, and inflammatory cells suggested a role for PDGF in wound healing. 
Similarly, the homology to the v-sis product implied a role in tumour 
progression. However, the wide expression of PDGFs, both during 
development and in disease implied additional features (see below). The 
PDGF superfamily of growth factors now com prises PDGF-A and -B, and 
the recently discovered PDGF-C and -D. These form, together with the 
members of the vascular endothelial growth factor family (VEGF-A, -B, -C, 
-D, -E and placenta growth factor), a PDGF/VEGF super-family of 
structurally related GDFs. 
Expression of PDGFs during development 
In mice, PDGF-A and PDGFR-a mRNA is present in pre-implantation 
oocytes, as well as during early post-implantation stages (Rappolee et al. 
1988; Mercola et al. 1990). At E7.5, the embryonic and extraembryonic 
ectoderm expresses PDGF-A, whereas the mesoderm expresses the a-
receptor. At El0-12, adjacent cells express the PDGF-A ligand and a-
receptor. For example; the surface ectoderm expresses PDGF-A, while the 
underlying dermatome expresses PDGFR-a. Similarly, the myotome 
expresses PDGF-A and the surrounding loose mesenchyme expresses 
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PDGFR-a (reviewed in Betsholtz 1995). Later, cells in the hair follicles, the 
lung and in the gastrointestinal tract show a similar paracrine expression 
(Lindahl et al. 1997b; Karlsson et al. 1999; Karlsson et al. 2000). 
In contrast to PDGF-A, only endothelial cells and megakaryocytes express 
PDGF-B during mouse development (Lindahl et al. 1997a). Adjacent cells, 
vascular smooth muscle cells/pericytes or their progenitors, express PDGFR-
ß (Hellstrom et al. 1999). A LacZ reporter gene insertion under the control 
of the PDGFR-ß promoter suggests that the heart, the somites and limb bud 
mesenchyme express PDGFR-ß transiently at E10 (Soriano 1994). 
The myotome, the epidermis, and the kidney express PDGF-C. However, the 
expression differs to some extent from PDGF-A and occasionally overlap 
with PDGFR-a (Ding et al. 2000; Aase et al. 2002). 
The vasculature, the heart and the kidney express PDGF-D. PDGF-D is one 
of the newly discovered PDGFs and the expression pattern is not extensively 
mapped (Bergsten et al. 2001; Uutela et al. 2001; Changsirikulchai et al. 
2002). 
In conclusion, expression of the ligands and receptors indicate paracrine 
signalling between epithelial/endothelial and mesenchymal cell types. 
Deletion of the PDGF-A or -B affects smooth muscle cell lineages in e.g. 
lung and kidney, respectively, thus being demonstrative for such signalling. 
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Genomic organisation of the PDGFs 
The seven PDGF-B exons encompass 24 kb of genomic sequence. The first 
exon contains untranslated sequences and a sequence that translates into a 
signal peptide for secretion. Exons two and three code for the amino 
terminal propeptide and the very first amino acids in the mature polypeptide. 
Exons four and five code for the major part of the mature protein, and 
thereby also account for the receptor binding capabilities. Exon six codes for 
a stretch of basic amino acids, which confer retention of the factor within 
and/or adjacent to the producing cell (see paper 1 and section below) and the 
last exon is non-coding. The genomic structure of PDGF-A is highly similar, 
though an alternate usage of the sixth exon results in two isoforms. The 
PDGF-C and -D genes consist of six and seven exons, respectively. The 
second and third exons encode a CUB-domain, which is unique for PDGF-C 
and -D within the PDGF/VEGF superfamily. The CUB domain is suggested 
to inhibit signalling and needs to be proteolytically removed for growth 
factor activation (Bergsten et al. 2001 ; LaRochelle et al. 2001 ). The fifth and 
sixth exons in PDGF-C encode the core domain. Similarly, the sixth and 
seventh exons encode the core domain in P DGF-D (see figure 2). PDGF-C 
and -D have no region homologous to the retention sequence found in 
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PDGF-A and -B (Heldin et al. 2002). 
PDGF-B 
Exons 1 
5-UTS 
PDGF-A 
PDGF-C 
cccccc cc, 
PDGF-D 
VEGF-A 
Figure 2. Outline of the genomic organisation of PDGF/VEGF gene family members. 
The genes are located on the following chromosomes: ch.7 pdgf-a\ ch.22 pdgf-b; ch.4 
pdgf-c; ch.l 1 pdgf-d. 5'and 3' untranslated sequences are shown for PDGF-B. Numbered 
black boxes indicate exons; lines, splicing pattern; grey boxes, sequences involved in 
receptor binding; arrows, known and hypothesised proteolytic processing sites; asterisks, 
translational stop codons; striped boxes, retention sequences encoding part of HSPG-
binding region; C, conserved cysteine residues; Cx, cysteine rich area. The CUB domains 
are encoded by exon two and three in PDGF-C and -D. Note that exon one is not drawn 
to scale in any gene (Dalla-Favera et al. 1982; Betsholtz et al. 1986; LaRochelle et al. 
1991; Raines and Ross 1992; Chilov et al. 1997; Keck et al. 1997; Robinson and Stringer 
200l;Uutelaetal. 2001). 
Receptor specificity and signal transduction 
PDGF stimulates cells of mesenchymal origin that express the receptor 
tyrosine kinases PDGFR-a and PDGFR-ß. PDGF-A and PDGF-C bind the 
PDGFR-a, while PDGF-D binds the PDGFR-ß. PDGF-B is unique in the 
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sense that it binds and activates both the a and ß receptor, either as BB 
homodimer or as AB heterodimer. PDGF-C and -D do not form 
heterodimers (reviewed in Hoch and Soriano 2003). Binding of PDGF-B to 
the receptor, induces PDGFR-ß dimerisation and subsequent 
transphosphorylation of intracellular tyrosine residues. The phosphorylation 
occurs both within and outside the kinase domain. Following activation, the 
receptor is internalised and degraded rapidly. Phosphorylation of tyrosine 
residues within the kinase domain increases the catalytic activity, while 
phosphorylated residues outside this domain provide binding sites for signal 
transduction molecules. Several proteins interact with PDGFR-a and 
PDGFR-ß through SH2 domains. The SH2 domain consists of 
approximately 100 amino acids and is present in downstream signal 
transduction molecules such as phosphatidylinositol 3' kinase (PI 3-kinase), 
phospholipase C (PLC-y), Scr kinase family members and GTPase activating 
protein (GAP). Within the PDGFR-ß, around 15 specific binding sites have 
been identified. All the molecules that bind through their SH2 domain can 
initiate a signalling cascade leading to e.g. cell growth, Chemotaxis and actin 
reorganisation. Downstream signalling molecules include important 
transducers such as rho and ras (reviewed in Heldin et al. 1998). PDGF-B 
contributes in the progression of various diseases such as cancer, 
atherosclerosis and fibrosis. Atherosclerosis is not mentioned or analysed in 
the papers included in this thesis, and I t herefore refer interested readers to 
other papers, for example Nature Medicine August issue "Special focus on 
atherosclerosis" 2002. 
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PDGF in cancer, fibrosis and glomerular disease 
Cancer 
Several studies support a role for PDGF-B in tumour initiation and/or 
progression. PDGF-B is a cellular form of the retroviral v-sis product and 
has the potential to induce cell transformation (Leal et al. 1985; Beckmann 
et al. 1988). Moreover, injection of SSV into marmosets or mice induces 
formation of fibrosarcomas and gliomas depending on injection site 
(reviewed in Heldin and Westermark 1999). PDGF-A and -B as well as their 
cognate receptors are present in a range of human tumours. In addition, 
genetic alterations in PDGFR-a (Fleming et al. 1992; Kumabe et al. 1992; 
Hermanson et al. 1996; Clarke and Dirks 2003), PDGF-B (Simon et al. 
1997) and in PDGFR-ß (Carroll et al. 1996) may produce active receptors in 
tumours. Several pre-clinical and clinical trials are ongoing with the aim to 
inhibit PDGFs and PDGF receptors. For example, imatinib (Gleevec) 
inhibits PDGFR-a, PDGFR-ß, Kit, Abl and Arg tyrosine kinase receptors, 
and has proven beneficial in certain leukemia and gastrointestinal tumour 
types (Capdeville et al. 2002). The compound SU11248 that inhibits 
VEGFR-2, PDGFR-ß and Kit, yielded promising results in a phase I clinical 
trial (Mendel et al. 2003). Chemotherapy is, in part hampered by high 
interstitial fluid pressure (IFP) in the tumour tissue. A combinatory treatment 
with a PDGFR-ß inhibitor (lowering the IFP) and chemotherapy, resulted in 
a significantly increased uptake of the chemotherapy agent (Pietras et al. 
2002). Other aspects on PDGF and tumour progression are discussed below 
in conjunction with paper II. 
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Fibrosis 
The ability of PDGFs to stimulate proliferation and Chemotaxis of 
fibroblasts and smooth muscle cells, and Chemotaxis of neutrophils and 
macrophages suggests that it might have a role in fibrotic reactions in 
different tissues, such as the lung. 
Characteristic for idiopathic pulmonary fibrosis is the accumulation of 
macrophages, neutrofils and mesenchymal cells (fibroblasts, smooth muscle 
cells and myofibroblasts). This leads to an increased accumulation of matrix 
components in the interstitial and intra-alveolar space. Vignaud and co­
workers showed a three times increase in the percentage of PDGF-B 
expressing macrophages during pulmonary fibrosis. The up-regulated levels 
of PDGF-B resulted in an increased number of mesenchymal cells and in 
increased matrix production (Vignaud et al. 1991). PDGF has been detected 
in several pulmonary diseases, and is thought to contribute to the 
progression of e.g. autoimmune-associated pulmonary fibrosis (Deguchi and 
Kishimoto 1989), histiocytosis X (Barth et al. 1991), acute lung injury 
(Snyder et al. 1991) and asbestosis (Lasky et al. 1996). Furthermore, in line 
with the data presented in paper III, lung specific transgenic over-expression 
of PDGF-B resulted in pulmonary fibrosis (Hoyle et al. 1999). Moreover, 
expression vectors for in vivo gene transfer resulted in a fibrotic response 
towards PDGF-B. In contrast, gene transfer of the extracellular domain of 
PDGFR-ß, which act as a PDGF trapping agent, markedly reduced 
bleomycin-induced fibrosis (Yoshida et al. 1995; Yoshida et al. 1999). In 
analogy to the anti-tumour therapy, using a PDGFR-ß specific inhibitor of 
the tyrphostin class inhibitors (AG 1296), mesenchymal cell proliferation 
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could be blocked and the amount of collagen could be decreased in a rat 
model of pulmonary fibrosis (Rice et al. 1999). 
Glomerular disease 
Deletion of either PDGF-B or PDGFR-ß in mice results in perinatal 
embryonic lethality and indistinguishable phenotypes (Leveen et al. 1994; 
Soriano 1994). There is, however, some discrepancy in the original 
publications, which report on different cardiac phenotypes. However, in 
subsequent analyses, identical phenotypes were shown (Mats Hellström and 
Mattias Kalén pers. comm.). Studies on these mouse mutants have shown 
that PDGF-B/PDGFR-ß is important for recruitment of supporting cells to 
the vasculature, including mesangial cells to the kidney glomeruli. Loss of 
mesangial cells led to ballooning of the glomeruli. In human 
glomerulonephritis, signs of the disease often coincide with abnormal 
PDGF-B expression. An excessive proliferation of mesangial cells, 
endothelial cells and neutrophils leads to a disturbed glomerular architecture. 
The increased number of cells, especially mesangial cells, leads to 
accumulation of ECM components in the glomerulus, so called mesangial 
matrix. Consequently, the filtration is disturbed and e.g. proteinuria can be 
clinically detectable. Yet, the aetiology is often unclear; however, several 
cytokines and growth factors, e.g. TGF-ß and PDGF-B, are likely to play a 
role. Several studies have detected an increased PDGF expression in 
mesangial proliferative nephritis (Gesualdo et al. 1991; lida et al. 1991; 
Yoshimura et al. 1991). Johnson and co-workers used a rat model in which 
an antibody (anti Thy 1.1), induces lysis of the mesangial cells. 
Subsequently, new mesangial cells invade and re-populate the glomerulus. 
By administrating a neutralising PDGF-B antibody, the proliferative 
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response could be significantly reduced, together with a broad inhibition of 
matrix deposition (Johnson et al. 1992). However, large doses of the 
antibody were used, which could result in a n immunoresponse towards the 
heterologous IgG. Therefore, the study could not continue beyond four days. 
The second attempt circumvented this fact by designing high affinity 
oligonucleotide aptamers specific for PDGF-B (Floege et al. 1999). 
Administration of the aptamer led to a steady decline in the number of 
mesangial cell mitosis. Eight days after the induction of glomerulonephritis, 
and six days after initiation of treatment, the number of proliferating 
mesangial cells had decreased by 95%. Additionally, PDGF-B blockade 
resulted in significantly decreased levels of fibronectin and collagen type IV. 
In a follow up study, the analyses continued for 100 days. In this study, 
PDGF-B aptamer treatment was shown to protect against the proteinuria that 
developed as a late complication to the anti Thy 1.1 treatment (Ostendorf et 
al. 2001). 
Clearly, increased PDGF-B levels are an important feature in the progression 
of glomerular disease. Conversely, through mutagenesis or antibody 
delivery, a few models have been developed providing the opportunity to 
follow the pathogenesis when a lower level of PDGF-B or impaired receptor 
signalling is prevalent (Klinghoffer et al. 2001; Sano et al. 2002). As a 
result, lowered or increased levels of PDGF-B seem to have a similar 
outcome. See Present Investigation and the Discussion sections for further 
details. 
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Specific background and Present investigation 
Paper I "Endothelial PDGF-B retention is required for proper investment of 
pericytes in the microvessel wall" 
Introduction to cellular retention 
The PDGFs show a high degree of evolutionary conservation in their 
genomic organisation and amino acid sequence. The comparison of PDGF-A 
in human, mouse and frog (Xenopus laevis) shows that the mouse amino 
acid sequence is 94% and 69% homologous to human and frog, respectively 
(Rorsman and Betsholtz 1992). PDGF-A and -B and VEGF-A contain an 
evolutionary conserved exon that codes for the retention sequence. The 
presence of a retention motif was implicated already in early studies of the 
v-sis and c-cis (PDGF-B) products. A major part of these products remained 
bound to the cell surface and only small amounts of incompletely processed 
factor were detected in tissue fluid of transformed cells (Robbins et al. 
1985). 
Alternative splicing of the PDGF-A gene results in alternate usage of a 
single exon. The alternative splicing of the sixth exon gives rise to two 
protein isoforms, namely PDGF-A-long and PDGF-A-short, with similar 
high affinity receptor binding capabilities (Ostman et al. 1989). These two 
isoforms are unequally distributed e.g. the two forms are equally expressed 
in kidney and thymus, but the short form dominates in muscle, heart and 
brain (Young et al. 1990). In transfected cells, they show a different 
distribution pattern (Ostman et al. 1991). By inhibiting proteolytic reactions, 
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LaRochelle and co-workers could show that the long form remains bound to 
the cell, while the PDGF-A present in the media does not contain the amino 
acid sequence encoded by exon six (LaRochelle et al. 1991). A similar 
splicing mechanism is used in th e vegf gene. Alternative usage of the sixth 
and seventh exons results in at least four distinct isoforms, which show 
different distribution profiles upon secretion from the cell (Houck et al. 
1991; Tischeret al. 1991). Thus, the presence of these exons in v-sis, PDGF-
B, PDGF-A and VEGF mediates similar distribution upon secretion from the 
cell. 
Identification of the cell retention signal 
Dimerised PDGF-BB localises to the endoplasmatic reticulum and the Golgi 
complex, from where it is transferred to lysosymes for degradation or 
transportation to cell membrane for secretion. A major part, however, 
remains cell-bound (Robbins et al. 1985; Thyberg et al. 1990; Ostman et al. 
1992). Several attempts have aimed to pinpoint by which mechanism the 
factor associates to the cell. The PDGF-B full-length protein is composed of 
241 amino acids. The design of four constructs carrying sequential stop 
codons positioned at amino acids 185, 211, 227 and 235 mediated functional 
mapping of the carboxy-terminal (C-terminal). When analysed in transfected 
cells, each product retained transforming capacity. Moreover, both the 235 
and 227 stop mutants were present only in cell lysate, whereas PDGF stop 
mutants 185 and 211 accumulated in the cell media. Consequently, the 
sequence responsible for the retention was denoted retention sequence and 
consists of a stretch of basic amino acids within the region 212-226 
(LaRochelle et al. 1991). In a similar study, the substitution of the C-
terminals of PDGF-A and PDGF-B led to altered protein distributions. 
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PDGF-A-short/B-COOH, distributed as PDGF-Bwt, whereas PDGF-B/A-
COOH distributed as PDGF-Ashort. In the same study, insertion of stop 
codons, similar to the approach above, at positions 191, 219 and 230, 
confirmed the presence of the retention sequence to this region, and 
narrowed it down to positions 219 and 230 (Ostman et al. 1991). 
The retention sequence carries potential proteolytic cleavage sites (Raines 
and Ross 1992; Westermark and Sorg 1993). A cleavage at the C-terminus 
would release the protein and enable it to diffuse away form the cell. 
Similarly, PDGF-B without the retention sequence would reach longer 
distances. This was also the case in an in vivo experiment. Keratinocytes 
transfected with expression vectors for PDGF-B-stop-211 induced a 
widespread formation of a thick connective tissue in a transplant. 
Keratinocytes expressing PDGF-Bwt instead induced a local response in th e 
connective tissue. Moreover, cells transfected with PDGF-B-stop-211 
released up to 20 times more of PDGF-B (Eming et al. 1999). 
mPDGF-B -R P P K G K H R K F K H T H 
mPDGF-A -R R m
 
CO
 
O
 
K N R K R K R L K 
mVEGF-A -V R G K G K G Q K R K R K K 
mPIGF-2 -R K T K G K R K R S R N S S 
Table 2. Alignment of the evolutionary conserved retention sequence in the COOH-
terminal in PDGF/VEGF super family members. Basic amino acids in bold. Modified 
from paper I 
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The retention sequence found in P DGF-A and -B is similar in both structure 
and function. Therefore, the homologous sequence found in VEGF would 
result in an analogous product. Expression of the vegf transcripts in an in 
vitro system showed that VEGF-121 and VEGF-165 accumulated in the cell 
culture media. The longer isoforms, VEGF-189 and VEGF-206 remained 
undetected in the media (Houck et al. 1991). In a follow up study, significant 
amounts of VEGF-165 accumulated in the cell media. However, a part 
remained extracellularily bound. In contrast, VEGF-121 displayed no signs 
of cellular retention (Houck et al. 1992). Consequently, the presence of the 
evolutionary conserved retention sequence in either PDGFs or VEGFs 
mediates retention of the secreted factor to the producing cell. As mentioned 
earlier, the importance of such retention may, in theory, include the 
formation of depots and gradients of importance for spatially restricted 
responses in developmental and pathological contexts. To test these ideas 
experimentally is a huge challenge. With recent advances in mouse genetics, 
however, it has been possible to specifically delete retention motifs in VEGF 
and PDGF family members. Indeed, published work show that the long 
retention-motif-containing splice isoforms of VEGF are important for the 
formation of VEGF gradients and that these gradients, in turn , are necessary 
for correct patterning of blood vessels (Ruhrberg et al. 2002; Stalmans et al. 
2002; Gerhardt et al. 2003). I adopted a similar approach to study the 
physiological function of PDGF-B retention. 
Creating a pdgf-b retention deficient mouse model 
In order to create an in vivo model to investigate the functional importance 
of the retention motif in the pdgf-b gene we set up a project aiming to delete 
this motif in mice. This rendered us with the possibility to study the 
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functions during development and in the normal state of an adult organism, 
as well as in a pathological state. The introduction of a subtle mutation to the 
pdgf-b locus presented us with several concerns. Firstly, we had to clone and 
further characterise t he region coding for the COOH-terminal. Secondly, we 
needed to introduce a translational stop codon, also containing a diagnostic 
restriction site, prior to the sequence coding for the retention motif. Thirdly, 
we had to introduce an antibiotic resistance gene to promote selection of 
recombinant embryonic stem-cell clones. LoxP sequences flanked the 
selection gene to enable excision by the help of cre-recombinase. Fourthly, 
we had to include enough homology to the target gene in the construct to 
enable recombination between the targeting construct and the pdgf-b locus. 
The homologous recombination involved the endogenous 5'end upstream of 
the selection marker, the 3'end directly downstream of the selection marker 
and the 3'end downstream of the stop-codon and diagnostic restriction site 
(see figure 3 A, B). By this approach, we managed to create mice whose 
genome differed from the wt only by eight base pairs in exon six (TAA-stop 
codon and Hindlll-site) and a 34 bp loxp sequence in intron f ive (after ere 
mediated excision, see figure 3 C). 
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Figure 3. Strategy to delete the pdgf-b retention sequence. A) Pdgf-b wt locus, where 
exon six codes for the retention sequence. B) Targeting construct including selection 
marker in intron 5, stop codon and diagnostic HindiII-site in exon six. C) The pdgf-b reI 
allele after ere mediated removal of selection marker. Modified from paper I. 
These mice should therefore be able to produce a freely, or at least a more 
freely diffusible protein upon sec retion, based on the data presented above. 
The characterisation of the pdgf-b re t/ret mouse is fully presented in pape r I, 
but the text below is intended to give additional background to the 
experiments performed and to explain the main findings, in ord er to set the 
stage for the discussion section. 
Functions of PDGF-B during vascular development 
Blood vessels forms through two distinct processes, vasculogenesis and 
angiogenesis. De novo formation of blood vessels is denoted vasculogenesis. 
Angiogenesis refers to the sprouting from pre-existing vessels and 
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subsequent vascular remodelling. Vasculogenesis begins in the splanchnic 
mesoderm of the yolk sac, where the pluripotent stem cells, hemangioblasts, 
form dense cell clusters, or so called blood islands. The outer cells of this 
transient structure develop into the lining endothelium, whereas the inner 
cells differentiate into blood cells. The outer lining endothelial cells (EC) 
start to connect and fuse, thereby creating the first primitive vascular plexus. 
The plexus then matures through angiogenic steps, including regression, 
sprouting and recruitment of coating mural cells (reviewed in Flamme et al. 
1997). 
Early reports pointed to expression of PDGF-B, as well as PDGFR-ß, in 
endothelial cells during embryonic development (Holmgren et al. 1991; 
Shinbrot et al. 1994). However, more sensitive detection assays localise 
PDGF-B in the developing endothelium, whereas the ß-receptor is detected 
in adjacent pericytes, vascular smooth muscle cells (vSMC) and mesangial 
cells (Lindahl et al. 1997a; Lindahl et al. 1998; Hellstrom et al. 1999). The 
genetic ablation of this signalling pathway results in identical and 
remarkably conclusive phenotypes. Organs dependent on angiogenesis such 
as the brain and the kidney, display severe vascular defects and an almost 
complete lack of pericytes (in the CNS) and glomerular mesangial cells (in 
the kidney). This leads to vascular dilatation, oedema, micro-aneurysms, 
hyperplasia and to ballooning of glomeruli. Organs dependent on 
vasculogenesis e.g. the liver, display no such alterations. This prompted us 
to begin our pdgf-b ret/ret analyses in organs where PDGF-B or PDGFR-
ß appeared indispensable. 
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Retinopathy in pdgf-b retlret mice 
The retinal vasculature develops in t he same way in mice and in humans. In 
mice, endothelial cells (EC) sprout from the optic disc immediately after 
birth. At P4, the EC have reached half the way to the retinal margin. The EC 
are closely associated to the astrocytic network, which reaches the retina 
periphery by this point in time. The vasculature reaches the same margin at 
P7. Simultaneously, sprouts from the veins spreads vertically downwards, 
into the retinal inner and outer plexiform layers, where they branch and fuse 
into a deep vascular plexus. The supporting mural cells, pericytes and 
vSMC, always follow the leading sprouting perimeter. They are never 
situated at the absolute foremost sprouts, but lag behind one or a few cell 
diameters. 
Although the pericytes, judged by their location, do not seem instructive for 
the retina vasculature, compelling evidence has recently emerged that point 
towards essential features of the pericytes. Mice heterozygous for PDGF-B 
display a 30% reduction in pericyte numbers, leading to a subtle effect on 
the vasculature (Hammes et al. 2002). Klinghoffer and co-workers further 
show that slight alterations in the PDGF-B/PDGFR-ß signalling pathway 
disturb the vascular patterning. Substituting the cytosolic signalling domain 
of PDGFR-ß with that of PDGFR-a on one allele and combining this with a 
pdgfr-ßnull allele, leads to severely distorted retinal vasculature. The 
mutants display a reduced number of pericytes, which are unevenly 
distributed over the retinal surface resulting in focal haemorrhages 
(Klinghoffer et al. 2001). Conclusions on PDGF functions in the retina had 
previously been based on either ectopic over-expression (Seo et al. 2000) or 
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on ectopic injections of PDGF-B protein (Benjamin et al. 1998). Therefore, 
Klinghoffer's study represents the first genetic evidence of a crucial role for 
PDGF signalling in the retina. Pericyte recruitment in the retina could also 
be inhibited by specific blocking of PDGFR-ß using antibodies, resulting in 
a similar distortion of the vasculature (Uemura et al. 2002). Recently, Enge 
et al presented elegant proof utilising EC-specific cre-recombinase/loxp 
mediated excision of the pdgf-b gene. Since Cre mediated excision is usually 
not taking place in all cells (of a certain type), Enge and co-workers 
analysed the phenotypic alterations in a wide range of pericyte depletion 
states. Up to 90% of pericyte deficiency is compatible with postnatal 
survival, though such reduction of pericyte density lead to severe 
retinopathy. Interestingly, there seems to be a threshold at about 50% 
pericyte reduction. Below this value, a vascular proliferative response 
occurs. Pericyte reduction above 50% results in focal vascular changes e.g. 
microanuerysms and vessel regression, however without a proliferative 
component (Enge et al. 2002). 
Basically, at the same time as these studies emerged, we observed that a 
fraction of the pdgf-b retention deficient mice showed macroscopically 
distinguishable white opacities in the lens. This led us to initiate a time-
course study on the eye and specifically on retinal development. 
Commencing at the onset of vascularisation from the optic disc, we found 
that the sprouting was irregular and severely delayed. Moreover, the retina in 
the pdgf-b ret/ret mice had a reduced pericyte density and certain areas were 
completely devoid of pericytes. Blood vessels were dilated, hyperfused and 
had no well-defined sprouting region. These abnormalities of early retinal 
vascularisation progressed and subsequently led to retinal degeneration and 
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formation of fibroblast-rich areas that spread over the retinal surface. In later 
stages, secondary alterations of the lens structure occurred and the retinal 
pigment epithelium invaded the retina. Furthermore, pericytes failed to 
integrate to the vessel wall in pdgf-b ret/ret mice at early stages, which 
implied that we observed more than a hypo-functional situation. However, 
this was not surprising, since we would expect a more diffusible protein 
from the mutation that we had introduced. The pdgf-b ret/ret mice display 
the most advanced type of abnormal retinal patterning among the models 
described above. This was surprising, since PDGF-B expression was 
maintained at the sprouting tip, however, at reduced levels. Consequently, 
correct localisation of the secreted protein is equally important as having a 
functional signalling pathway. 
Kidney and glomeruli development 
The vertebrate kidney is formed through an extensive cross-talk between 
cells of epithelial and mesenchymal origin. The kidney starts to develop as 
early as E8 in mice and day 22 in humans when inductive signals from the 
nephric duct reach the adjacent mesenchyme and stimulate the formation of 
pronephros and subsequently mesonephros. These structures are transient, 
although a part of the mesonephros persists and contributes to the sperm-
carrying ducts in m ales. Moreover, the mesonephros is a producer of blood 
cells over a limited time during development (pronephros is a functional 
kidney in fish, but is not thought to be active in mammals). The 
metanephros, the functional vertebrate kidney, arises from an outgrowth of 
the nephric (wolffian) duct. The branch, referred to as the ureteric bud, 
responds to signals from the metanephrogenic mesenchyme and develops 
through reciprocal interaction into ureter, renal pelvis and collecting ducts. 
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The glomerular structure first appears as mesenchymal condensates at the tip 
of the ureteric branches. In the formation of the glomeruli, the condensates 
undergo mesenchymal-to-epithelial conversion and subsequently develop 
through the readily distinguishable comma-, S- and cup-shape bodies. The 
upper part of the S-shape body gives rise to the proximal tubule, loop of 
Henle and the distal tubule that connects to the ureteric branch, which 
generates the collecting ducts. Other parts of comma- and S-shapes bodies 
develop into glomerular visceral epithelial cells and parietal epithelial cells 
that constitute the lining of Bowman's capsule. Vascularisation of 
metanephros takes place when the first ureteric branches form. The 
vasculature becomes evident in the cleft of the S-shape stage. The origin of 
the invading mesangial and endothelial cells is unknown, but both 
vasculogenic and angiogenic processes are suggested. These data will not be 
discussed here and I refer to (Ricono et al. 2003) and references therein. 
Functions of PDGF-B in glomeruli formation 
It is clear that PDGF-B/PDGFR-ß mutants are affected in organs were 
angiogenesis is the main process in the establishment of the vascular bed. 
Evidently, these mutants display abnormal vascular morphogenesis in the 
kidney glomeruli. PDGF-B is expressed both by the capillaries that grow 
into the S-shape as well as in afferent/efferent vessels, while expression of 
PDGFR-ß is detected in vessel associated cells in the S-shape (but not in the 
comma shape). Cell populations located at the core of the glomeruli are 
positive for both PDGFR-ß and the mesangial marker desmin. PDGFR-ß in 
situ hybridization also labels a small cluster of cells at the cup-shape state 
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that, most likely, reflects mesangial cell precursors. In the PDGF-B/PDGFR-
ß mutants, these cells fail to contribute to the mature glomeruli. Instead one 
or a few endothelial tufts form that are completely devoid of mesangial cells, 
which makes the glomeruli appear as a balloon shaped structure filled with 
erythrocytes (Leveen et al. 1994; Soriano 1994; Lindahl et al. 1998). This 
suggests that the kidney is sensitive to alterations in the PDGF signalling 
system and furthermore, that these signals are essential for proper glomeruli 
development. 
Abnormal glomeruli formation in pdgf-b ret/ret mice 
A correct spatial localisation of PDGF-B might, hypothetically, be critical 
for proliferation, migration and survival of the mesangial cells. Thus, we 
undertook an in depth characterisation of the glomeruli in the pdgf-b 
retention deficient mice. We analysed embryos from El5 to El8 using 
hematoxylin/eosin, pecaml and a-smooth muscle actin staining. All the 
embryos analysed phenocopied, to a major extent, the PDGF-
B/PDGFR-ß mutants. Virtually all mature glomeruli completely lacked, or 
contained very few, mesangial cells and the single capillary loop within the 
glomerulus was extensively dilated (ballooning glomeruli). The viability of 
pdgf-b ret/ret m ice offered a unique possibility to follow the consequences 
of the mesangial cell loss at the postnatal stage. Surprisingly, the glomeruli 
recovered remarkably fast, the contribution of mesangial cells had by P5, 
increased dramatically, and was normalised at P30. Interestingly, at later 
stages the picture was again pathological, with several signs of a 
glomerulosclerotic condition. The individual effect on each glomerulus 
varied from a single sclerotic loop (focal sclerosis) to fully sclerotic 
glomeruli, which contained fewer mesangial cells instead replaced by 
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collagen, fibronectin and other extracellular matrix substances. Not only 
were the glomerulus tuft affected, but we also detected thickening of the 
basement membrane in the Bowman's capsule. These findings may, at least 
in part, explain the increased levels of albumin that were present in the urine 
from the age of three months. The glomerular structure served as a good 
model to analyse the effect of varying doses of PDGF-B. Therefore, we 
compared glomeruli during development in pdgf-b +/+, pdgf-b ret/+, pdgf-b 
ret/ret, pdgf-b ret/- and pdgf-b-/- mice The numbers of recruited mesangial 
cells were clearly dependent on the theoretical dose of PDGF-B. The pdgf-b 
ret/- and pdgf-b -/- were phenotypically indistinguishable at E17 and had 
their mesangial cell core replaced with a blood filled cavity. Pdgf-b ret/ret 
mice displayed a similar phenotype, but the effect was not as dramatic and 
as penetrant. Pdgf-b ret/+ and pdgf-b +/+ mice showed an equal 
contribution of mesangial cells to the glomerulus core, as judged by light 
microscopy. Thus, genetic data pointed towards a hypomorphic situation in 
the pdgf-b ret/ret mice. We performed similar analyses in the CNS using a 
pericyte specific LacZ marker, with comparable results (see paper I). 
RNA and protein studies on pdgf-b ret/ret mice 
In order to achieve mechanistic insight into the morphological disturbances 
that occurred, both transcript and protein levels, as well as protein 
localisation, needed to be determined. RNA from pdgf-b +/+, pdgf-b ret/+ 
and pdgf-b ret/ret P21 mice was prepared and subjected to northern blot 
analysis, which pointed to an approximately 50% reduction in the mRNA 
levels in pdgf-b ret/ret mice. To analyse the protein distribution, we 
established primary endothelial cell cultures. However, these primary cells 
did not survive enough passages required for metabolic labelling. Therefore, 
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we produced endothelioma cell lines. With these cells we performed several 
attempts to immunoprecipitate PDGF-B following metabolic labelling, but 
failed to detect the protein either in wt or in pdgf-b ret/ret cells. While 
disappointing, this was not unexpected, since previously published data on 
PDGF-B protein detection by similar methodologies have all been 
performed on transfected cells expressing large amounts of recombinant 
PDGF-B. To our knowledge, no one has been able detect endogenous mouse 
PDGF-B satisfactorily by immunological techniques. However, using 
PDGF-B binding aptamers (Fredriksson et al. 2002), which are able to detect 
very low amounts of PDGF-B, a five fold reduction of protein content in the 
pdgf-b ret/ret cell line was observed (paper I). This study also showed that, 
albeit with lower total levels, secretion of PDGF-B into the medium was 
significantly higher in the pdgf-b ret/ret cells compared to the wt. In 
addition, quantification of PDGFR-ß receptor phosphorylation inducing 
activity had similar outcome. This also supplied an important finding; the 
PDGF-B ret product had maintained bioactivity. 
PDGF-B is required for proper developmental blood vessel formation and is, 
in addition, present in tum our types of several different origins (reviewed in 
Heldin and Westermark 1999). Moreover, tumour vessels express PDGF-B. 
To what extent is the embryonic angiogenesis, and pericyte recruitment, 
similar to a rapid growing tumour, with a different matrix composition and 
eventual lack of basement membrane? The pdgf-b ret/ret mice could, 
therefore, be used as a loss-of-function tool to address the role of 
endogenous PDGF-B in tumour development. 
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The role of PDGF-B/PDGF-RB in tumour angiogenesis 
- introduction 
In the current view, angiogenic endothelial cells establish a vascular plexus 
and concomitantly recruit mural cells. A well-studied example is the mouse 
retina, where the endothelial cells grow towards a source of VEGF and 
simultaneously recruit coa ting cells as they reach the retina perimeter. The 
mural cel ls are, however, always slightly lagging behind the front sprouting 
region. Furthermore, the origin of the mural cells is unclear, but the 
endothelium may in duce precursor cells to differentiate and by such means 
attract pericytes/vSMC. Another scenario is that the end othelial cells induce 
the pericytes/vSMC to migrate along the vessels. It is most likely that both 
of these mechanisms occur in vivo and the mural cells are, once recruited, 
essential for normal blood vessel function, as demonstrated by several 
studies. Unless covered by mural cells, the retinal vasculature is more 
sensitive to pruning (Benjamin et al. 1998). Moreover, complete absence of 
brain pericytes, as in PDGF-B/PDGFR-ß mutants, leads to endothelial 
hyperplasia with an approximate 60% increase of endothelial cells 
(Hellstrom et al. 2001). Similarly, a reduction of pericyte density by 50%, 
using specific removal of endothelial PDGF-B, results in an endothelial 
proliferative response (Enge et al. 2002). This finding is in agreement with 
earlier observations suggesting that pericyte drop-out preceded proliferative 
diabetic retinopathy (Speiser et al. 1968). Finally, studies on transplanted 
polymeric scaffolds containing VEGF and PDGF revealed measurable 
effects on the vessel d ensity. VEGF-A alone induce a higher vessel density, 
but the vessels are small and not properly formed. PDGF-B, on the other 
hand, does not produce more vessels, but more mature vessels, as judged by 
staining for a vSMC marker. Interestingly, a dual simultaneous 
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administration of PDGF and VEGF, where VEGF is released more rapidly 
than PDGF-B, results in higher blood vessel density and in more mature 
blood vessels (Richardson et al. 2001). Thus, pericytes and smooth muscle 
cells have more functions than just to act as stabilising and supportive 
compounds on the endothelium, and their presence have implications for the 
actions of VEGF. Data imply that endothelial c ells lacking covering mural 
cells are more sensitive to VEGF withdrawal. Indeed, in a mouse glioma 
model and in a primary human prostate cancer ablation of VEGF led to 
apoptosis of endothelial cells that were immature, in the sense that they were 
not covered with mural cells (Benjamin et al. 1999). In line with these data, 
and as described in t he general background, several trials have focused on 
antagonising receptor tyrosine kinases (RTKs). In a study by Gee et al, anti-
angiogenic treatment decreased the total vessel density, but significantly 
increased the relative number of vessels with a mural coating (Gee et al. 
2003). Recently, Bergers and co-workers provided conclusive data by 
targeting both PDGFR-ß on mural cells and at the same time inhibiting 
VEGF receptor signalling. Here, tumour vessels were reduced and the 
combined approach led to regression of late-stage tum ours (Bergers et al. 
2003). Those data were published during the time we were preparing the 
paper II manuscript and they support our own conclusion s. I will summarize 
the most important observations and the e xperiments we performed to be 
able to understand the mechanism by which PDGF-B and PDGFR-ß are 
involved in pericyte recruitm ent to the tumour vasculature, 
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Influence of PDGF-B/PDGFR-ß on the tumour vasculature 
Wildtype and pdgf-b ret/ret mice were transplanted with a mouse 
fibrosarcoma cell line, T241. We chose the T241 cell line because a 
comparatively high proportion of the tumour vessels have mural coating and 
show a relatively normal morphology compared to the tumour vessels in 
many other models that have been studied by us and others. Tumours grown 
on pdgf-b ret/ret mice were, after 12 days, more haemorrhagic and had a 
looser consistency upon dissection, but no obvious difference in tumour size 
was observed. However, the tumour vasculature differed remarkably: vessels 
were dilated, pericytes were detached and pericyte coverage was 
significantly reduced. Thus, endogenous PDGF-B was not present in 
adequate amounts in the pericellular space surrounding the vessels to 
support "normal" vessel formation in the T241 tumours. 
Several described tumours express PDGF-B, although not the T241 cell line. 
To analyse the effect of tumour-derived PDGF-B on smooth muscle cell 
recruitment, we used a CMV promoter to drive the expression of human 
pdgf-b cDNA in T241 cells. This provided us with four types of tumours; 
T241 on wt, T241 on retention mice, T241-B-transfected on wt and T241-B 
transfected on retention mice. Briefly, the vessel diameter in the T241-ret 
tumours were two-fold wider than in T241-wt, but showed no significant 
change in vessel density. More than half of these vessels had no contact with 
mural cells. Interestingly, the vessel diameter was normalised in T241-B-ret 
tumours, reflecting the fact that the pericyte coverage was significantly 
increased from 4% in T241-ret compared to 15% in T241-B-ret and 17% in 
T-241 to 36% in T-241-B. In addition, the pericytes that connected to the 
vessels in T24l-ret and T241-B-ret did not invest the vessel wall properly. 
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For instance, 4% of the mural cells in T241 -wt extended further than 10 |Um 
away from the vessel, while the comparable proportion was 80% in T 241-
ret. 
Next, we injected a mixture of T241 cells and cells that originated from wt 
and PDGFR-ß deficient mice, also harbouring a transgenic pericyte marker. 
This rendered us with the possibility to prove that PDGF-B plays a major 
role in the recruitment of mural cells to the tumour vessels. No difference 
was observed between the numbers of recruited mural cells in tumours 
transplanted to wt or pdgf-b ret/ret mice. Thus, the recruitment of 
exogenously added pericytes was clearly not dependent on PDGF-B 
retention, but pr oper integration into the vessel wall still fai led. Importantly, 
we thereby show an absolute requirement for the expression of PDGFR-ß on 
the exogenously added pericytes to enable their recruitment; since no such 
cells were present adjacent to the endothelium. We further show that lo ss of 
PDGF-B retention results in de fective integration of pericytes to the micro­
vascular wall (in line with the published data in paper I), and affects the 
tumour vascular patterning. 
From published literature and the findings in paper I and II, it is clear that 
retention of PDGF-B to the pericellular space is indispensable during 
development and exerts analogous functions during tumour progression. 
Recruitment of pericytes and vSMC is apparently the most important 
developmental function for PDGF-B and PDGFR-ß. However, gene-
targeting experiments only depict fundamental roles for each gene; other 
roles, which may be important, but lack a morphological consequence might 
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go undetected. The actions of PDGF-B are important in several fibrotic 
conditions. PDGF acts through activation of PDGFR-a and 
PDGFR-ß, expressed on fibroblasts and induces mitosis and matrix 
production. Such signalling is likely to occur e.g. in th e heart where PDGF-
A is expressed by cardiac myocytes and PDGFR-a by cardiac fibroblasts. 
The deletion of PDGFs or PDGF receptors has provided very limited 
information concerning the functions of PDGFs during cardiac development. 
For example, do the dilated hearts in PDGF-B mutants reflect a direct role 
for PDGF on cardiac fibroblasts? Or are the cardiac defects secondary to the 
vascular malformation? Are the actions of PDGFs mainly of developmental 
importance or are these factors also effective in the adult? With the aim of 
investigating the effect of PDGF in the heart, we placed the a-myosin heavy 
chain (a-MHC) promoter in control of the expression of the short, freely 
diffusible form of PDGF-A, the long heparin binding PDGF-A isoform and 
PDGF-B, and generated transgenic mice using these constructs. 
Paper III "Heart specific over-expression of different platelet-derived growth 
factor isoforms results in varying degree of cardiac fibrosis" 
Derivation of a-MHC-PDGF transgenic mice 
The transgenic a-MHC promoter mimics the endogenous myosin heavy 
chain expression in the heart (Subramaniam et al. 1991). During 
development, the main MHC isoform is the ß-MHC. At birth, a shift 
towards a-MHC isoform occurs. Therefore, we expected no dominant effect 
of the trangenes during embryogenesis and the major changes that we could 
observe occurred postnatally. We designed three similar transgenic 
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constructs, by joining the a-MHC promoter to human cDNA coding for 
PDGF-A-long isoform (PDGF-AJ, PDGF-A-short form (PDGF-AS) and 
PDGF-B. All constructs terminated in a poly A signal, derived from the 
human growth hormone 3'end. 
Cardiac fibrosis in a-MHC-PDGF transgenic mice 
We identified four postnatal founders f or each construct. Over-expression of 
PDGF-AL resulted in postnatal lethality at around three w eeks of age, due to 
extensive enlargement of the heart. Comparably, over-expression of 
PDGFAs caused a similar, but milder, cardiac hypertrophy and 
consequently, lethality at s ix to eight weeks. As expected from the t ime of 
death, we detected the most severe disturbances in the PDGF-AL transgenes 
where an extensive amount of collagen was interspersed between the muscle 
layers. Moreover, the response to the elevated doses of PDGF-A was not 
limited to focal sites, but spread over the entire myocardium. Since over-
expresssion of PDGF-C has recently been shown to induce cardiac f ibrosis 
accompanied by vascular changes, we stained the vascular compartment in 
the PDGF-A transgenic hearts with a-smooth muscle actin (SMA) and 
Pecaml. This revealed decreased capillary density around the myoFibres an d 
an increased number of dilated and irregular vascular structures (paper III). 
The a-MHC PDGF-B positive founders seemed healthy and viable, and two 
of them were sacrificed for analysis at s even months of age. They displayed 
an approximate three-fold increase in the siz e of the heart, and staining using 
MTC revealed focal deposits of collagen. The collagen was not present in 
such high amounts as in PDGF-AS, which made the muscle layers appear 
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normal, except for areas were collagen deposits were dense. Similarly, the 
two other founders analysed at ten months, showed focal fibrosis and 
collagen accumulation. Since PDGF-A induced the most severe responses; 
we assumed that the observations were dependent on signalling over the 
PDGFR-a expressed by cardiac fibroblasts. Confirming this idea, we 
detected the PDGFR-a in the ventricle and atrium wall by in situ 
hybridisation in w t mice. In PDGF-AS transgenes, expression of the receptor 
coincided with focal thickening of the atrium wall, most likely reflecting 
proliferative cardiac fibroblasts. PDGFR-a was also expressed on one side 
of the cardiac valves. In conclusion, PDGFs influence cardiac fibroblasts 
and induce proliferation that eventually leads to myocardial hypertrophy. 
We can also conclude that each of the PDGF isoforms contribute to various 
extents to the progression of cardiac fibrosis. 
General Discussion 
Despite the lack of detailed information of GDF-ECM interaction and their 
physiological relevance, virtually all biological systems appear to utilise the 
growth factor retention. There appears not to be one single mechanism 
governing extracellular GDF distribution, but a variety of means that 
eventually leads to specific localisation of the factor. In PDGF/VEGF 
superfamily, a specific motif rich in basic amino acid residues mediates 
interactions with the ECM and maintains the factor in close vicinity of the 
producing cell. However, other mechanisms exist that confer cellular 
retention. Secreted TGF-ß, for example, consists of a complex of subunits 
with different functions. The secreted protein binds to associated proteins 
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that in turn have matrix- interacting capabilities. Activation of the factor 
requires proteolytic removal of associating proteins. EGF and TGF-a family 
members represent a third way. These molecules carry hydrophobic 
stretches that integrate into the cell membrane. Apparently, this is an 
evolutionary conserved feature since Drosophila homologues to Notch and 
Delta and the nematode Caenorhabditis elegans proteins lin-12 and glp-1 
share similar membrane-binding characteristics (Massague 1990). The 
number of factors utilising similar themes are still growing and now include, 
apart from the above, FGF, IGF-1, SCF, CSF-1, wnt-1, Hh and HGF family 
members (reviewed in Gallagher 2001 ; Iozzo 2001 ). 
Functions of GDF-ECM interaction 
The function of pericellular retention is probably dependent on the type of 
interaction, the growth factor and the intended signal. It is possible to 
imagine several theoretical scenarios. Since the retention sequence in the 
PDGF family is evolutionary conserved and considering the actions of 
PDGF-B, extracellular deposits of the growth factors might be of 
physiological relevance in response to cellular stress e.g. tissue damage. 
Rapid release of growth factors from such reservoirs through matrix 
degradation would be possible without the need to initiate transcription. 
Thereby, the necessary wound healing response can occur quickly. Another 
function might involve autocrine stimulation (where the signal activates 
receptors expressed by the same cell). Autocrine signalling is a debatable 
feature of PDGF, but several studies imply possible autocrine PDGF-B 
signalling with implications for tumour progression (Betsholtz et al. 1984; 
Leal et al. 1985; Beckmann et al. 1988) and for wound healing (Crosby et al. 
1999). Furthermore, presentation of a growth factor in close proximity to the 
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producing cell might facilitate direct cell-to-cell signalling. The membrane 
bound notch/delta and ephrin/eph ligand and receptor pairs, demonstrate 
such signalling. However, the analyses we performed do not rule out the 
possibility that s ecreted factors also would benefit from such presentation. 
We show in both paper I and paper II that pericytes fail to integrate into the 
vessel wall, which can be explained by al tered presentation of PDGF-B on 
the endothelial cell surface. Furthermore, we detected expression of PDGF-
B at the absolute tip of the sprouting retinal endothelium. The restricted 
expression might reflect the need for precise localisation of the growth factor 
to this region (see figure 4). Another possibility is tha t cellular retention is a 
way for the cell to further control the signal to reach the correct receptor-
expressing cell. In a situation where the receptor is widely expressed, the 
signal must be restricted. For example, the c-ret receptor is expressed along 
the nephric duct during kidney morphogenesis. The outgrowth and 
formation of the ureteric bud only takes place close to the metanephrogenic 
mesenchyme, which produces glial-derived neurotrophic factor (GDNF) 
(reviewed in Schedl and Hastie 2000). Hypothetically, if GDNF was to 
diffuse further from the source, the ureteric bud might not form or develop at 
an ectopic site. A similar function involves the creation of a gradient that 
results in varying cellular responses, depending on the actual dose the cell 
receives. For example, the TGF-ß superfamily member decapentaplegic 
(dpp), patterns the Drosophila wing through a gradient (Lecuit et al. 1996). 
Similarly, formation of a sonic hedgehog (Shh) gradient during neural 
development differentially influences the neural tissue. Shh, secreted from 
the neural tube, induces adjacent tissue to differentiate to motor neurons or 
interneurons depending on the concentration of Shh (Ericson et al. 1996). 
More speculative, and potentially concurrent with the above, is that the 
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receptor-expressing cell needs to bind a substantial number of molecules to 
induce signal transduction. For example, a particular mouse fibroblast cell 
line carry approximately 25,000 PDGF-a receptors and 40,000 PDGF-
ßreceptors (Simm et al. 1992) and adult rat cardiac fibroblasts carry 
approximately 15,000 PDGF-a and 25,000 PDGF-ß receptors (Simm et al. 
1997). In addition, the induction of a migratory response requires less 
PDGF-B, than the induction of a proliferative one. (Grotendorst et al. 
1982b). Thus, what proportion of these receptors requires activation to 
induce a full proliferative and/or migratory response? The amount of cellular 
retained factors that influences patterning and moiphogenesis involves 
numerous GDF families, each with a capacity to influence the state of the 
cell. It is tempting to speculate that the factors the cell faces during 
migration or growth supplies the cell with information of the processes that 
recently occurred. The ECM thereby functions as a "matrix-stored memory". 
If this was the case, the cell can express proper developmental spatial and 
temporal signals, or for instance, instruct the cell to end proliferation or to 
start production of extracellular matrix substances. These hypothetical 
functions of cellular retention are based on more or less well-founded studies 
and theoretical arguments, but I h ave to point out how few published in vivo 
experiments that have aimed at answering such questions. Several studies on 
ECM molecules in Drosophila and mice result in complex phenotypic 
alterations that could include several pathways and the mechanistics are 
often unclear. 
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Functional studies on GDF cell association 
The most well-characterised protein in terms of functions and properties of 
extracellular retention is VEGF-A. As previously described, alternative 
splicing leads to the formation of at least four VEGF-A isoforms. The 
shortest form (VEGF120) lacks the heparin binding sequence encoded by 
exon six and seven and is freely diffusible after secretion, while the longer 
form (VEGF]88) that contains these sequences accumulates pericellularily. 
The isoforms containing one of these sequences distribute at an intermediate 
frequency (Houck et al. 1992). Mice engineered to express only the short 
form displayed several angiogenic defects that resulted in ischemic 
cardiomyopathy (Carmeliet et al. 1999), impaired skeletal formation (Maes 
et al. 2002; Zelzer et al. 2002) and abnormal development of the brain and 
retinal vasculature (see figure 4) (Ruhrberg et al. 2002; Stalmans et al. 2002; 
Gerhardt et al. 2003). Collectively, these studies point to a requirement for 
tight regulation of the VEGF protein distribution. Alterations in the 
distribution pattern were detrimental in multiple ways. Moreover, these 
studies provided the first series of evidence for the importance of correct 
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GDF distribution in a vertebrate system. 
PDGF-B 
PDGF-B 
Figure 4. A conceptual illustration of PDGF/VEGF cell retention. A) The endothelium is 
guided toward a deposit of stored VEGF. PDGF is expressed by the tip cell and is 
retained in c lose vicinity to the endothelium, to which pericytes are recruited. B, In the 
absence of retention sequences, PDGF/VEGF are more diffusible, resulting in defective 
investment of pericytes to the vascular wall, endothelial hyperplasia, increased number of 
sprouts and altered guidance of the endothelium. Based on and modified from (Ruhrberg 
et al. 2002; Gerhardt et al. 2003 and paper I and II). 
The analyses I present in this thesis further strengthen this concept. It is a lso 
clear that the generation of mouse mutants, carrying subtle alterations of 
specific exons is time-consuming and require careful technological 
consideration and morphological analyses. Conversely, altering ECM core 
protein or heparan sulfate polymerization enzymes by conventional gene 
targeting is more straightforward, but the consequences of such mutations 
can result in complex phenotypes or redundancy. It is also possible that 
redundancy is not as common for highly conserved exons that code for 
protein distribution signals. However, I favour both approaches and they 
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should be used in parallel. Evidently, our data are limited, in the sense that 
we have not been able to detect the PDGF-B protein in tissues despite 
numerous attempts. Furthermore, the mRNA and protein levels were 
reduced in pdgf-b ret/ret mice, for reasons that are debatable. The alterations 
of the gene could per se alter the expression, which would seem unlikely 
when we have a 34 bp lox sequence in an intron as the only difference from 
the wt. A cellular feedback mechanism may exist, since the retention 
sequence also mediates intracellular retention. It is hard to imagine, though, 
that loss of intracellular retention should lead to a general down-regulation 
of PDGF-B expression. We do not know if the down-regulation is the actual 
cause of defective pericyte recruitment, or a consequence. Nevertheless, 
mice with an endothelial specific pdgf-b deletion do not show similar 
defective pericyte integration to the vessel wall, despite up to 90% reduction 
in pericyte density. The severity of the retinal phenotype points to more than 
just a down-regulation. Moreover, the cell culture data pointed to a more 
diffusible PDGF-B protein in pdgf-b ret/ret cells. 
The third paper describes how different isoforms of PDGFs can affect the 
proliferation of cardiac fibroblast at the postnatal stage. Also in this study, 
differences in the effect mediated by the long heparin binding form differ 
from those induced by the freely diffusible form. However, the outcome may 
reflect altered expression levels depending on the genomic integration site. 
Thus, we do not wish to draw too strong conclusions. Previous attempts to 
over-express PDGF-A and -B have been limited to lung (Hoyle et al. 1999) 
and eye (Seo et al. 2000) and the deletion of either PDGF ligands or 
receptors have not conclusively shown a direct effect of PDGF in the heart. 
On the one hand, up-regulated levels of PDGFs, either achieved by 
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transgenic approaches or in pathological models, induce a fibrotic response. 
This is, most likely, independent of the organ analysed, as long as the 
expression of ligand and receptor coincides. On the other hand, this thesis 
shows that a PDGF-B down-regulation has a similar outcome. Thus, 
physiological levels of available PDGF are maintained within a narrow 
concentration range and deviations from these levels, either by altered 
expression or by distribution, are detrimental. Clearly, these data are in line 
with the attempts to antagonize the effect of PDGFs, by other means than 
genetical. These attempts show promising results in the treatment of fibrosis 
and the inhibition of certain tumours. 
Conclusions and future perspectives 
In this thesis, 1 have tried to illustrate pieces of the high complexity in the 
construction of an organism and the functional organs. In addition, I have 
shown how both subtle as well as general genetic manipulation in the mouse 
can deepen our understanding of the physiological functions of proteins. 
This presents us with highly specialised tools to decipher the complex nature 
of our genome. In conclusion, we show in paper I that retention of platelet-
derived growth factor-B is necessary for recruitment of mesangial cells to 
the developing kidney, for recruitment of pericytes to the central nervous 
system and for correct development of the retinal vasculature. We showed 
that retention of PDGF-B is necessary for maintenance of functional kidney 
glomeruli in the adult and that ablation of the retention sequence led to 
glomerulosclerosis and proteinuria. In paper II we used this model to study 
whether the mechanism of pericyte recruitment during tumour progression 
was similar to developmental angiogenesis. We showed that PDGF-B and 
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PDGFR-ß had pronounced influence on the pericyte recruitment and 
vascular patterning in a tumour model. To create further understanding of 
the phenotypic changes several studies are ongoing. Firstly, the pdgf-b 
ret/ret mice are subjected to physiological studies that aim to determine the 
effect of altered PDGF-B signalling in cardiac, renal and vessel function 
(Nyström H., Lindblom P., Bergström G unpublished). Secondly, the pdgf-b 
ret/ret mice are used for studying the sequential changes in the kidney gene 
expression, from the embryonic mesangial cell loss, through a phase of 
recovery, to the adult stage of glomerulosclerosis (Norlin J., Lindblom P. 
and Takemoto M. unpublished). This approach allows the discovery of novel 
genes important for disease progression in the kidney. The approach may 
also give us insight into the mechanisms of mesangial cell recruitment and 
function. Thirdly, the use of the retention deficient mice in a femoral artery 
ligation assay aims to study the involvement of PDGF-B in arter iogenesis 
(Lindblom P. and Schaper W. unpublished). Fourthly, we aim to continue 
the use of the retention deficient mice as a model system to analyse 
mechanisms of sprouting tumour angiogenesis, and to further study the 
effect of angiogenic inhibitors in presence and absence of pericytes, 
(Abramsson A. and Lindblom P. unpublished). Other future objectives 
involve the identification of potential binding substrates for PDGF-B that 
mediate cell retention. Studies are ongoing to compare defective integration 
of pericytes to the micro-vascular wall in the pdgf-b ret/ret mice and those 
aberrancies found in the HS PG polymerase NDST-1 null mutant s (Gerhardt 
H. and Abramson A. pers.comm). As described in the introductory part, 
PDGF interacts with the ECM protein SPARC. We examined the 
development of the retinal vasculature in SPARC null mutants. However, we 
did not detect any retinal disturbances (Lindblom and Gerhardt 
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unpublished). Moreover, it would be interesting to design constructs that 
allow in vivo tracing of PDGF. To combine this with alterations of the 
distribution, such as deletion of retention sequences, mutagenesis of 
potential proteolytic processing sites or switching between retention 
sequences in different genes, would allow further mechanistic insight. 
Obviously, it is tempting to speculate about the functions of retention in 
other GDF families. 
In paper III, we show that different PDGFs can be involved in the 
pathogenesis of myocardial diseases by affecting cardiac fibroblasts. This is 
the first study that over-expressed two PDGF-A isoforms in vivo, and we 
could also detect differences in the responses they induced. From this study, 
we do not wish to conclude that the cause of the discrepancies is solely due 
to alterations in the splice forms, but it is tempting to speculate that they can 
induce different responses. Future experiments should aim to use inducible 
systems, since potent growth factors often lead to organ failures, which 
hinder adequate expression studies. The published transgenic lines that over-
express PDGF do not recapitulate the endogenous expression. Instead, it 
would be of high interest to study the effect on vascular smooth muscle cell 
recruitment in the presence of prolonged and increased PDGF-B expression 
from endothelial cells. In such experiment, using genes coding for products 
with altered distribution capabilities could increase the understanding of 
PDGF-B signalling. So far, embryonic lethality of transgenic founders has 
hampered our attempts to do so. (Betsholtz and Lindblom unpublished). This 
clearly highlights the need for inducible systems. 
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